Watch Dr. Goldberg’s presentation below regarding localized treatment of cancers in a more safe and effective way and the positive results derived from preclinical studies.
Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more
Privo CEO, Dr. Manijeh Goldberg, is invited to speak at the BioNetwork Partnering Summit. read more
Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more
PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more
Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more
PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more
Privo is excited to share the recent Forbes article titled, "Going Beyond Target Or Mechanism Of Disease: Disruptive Innovation... read more
Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more
PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more
- © Web Design & Development
- © UX Strategy & Digital Branding